Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.

IF 10.2 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-09-09 DOI:10.1158/1078-0432.ccr-25-2546

Steven Blinka,Evan Y Yu

引用次数: 0

Abstract

Human Kallikrein 2 (KLK2) is a prostate cancer tissue specific protein that is regulated by androgen receptor (AR) signaling. KLK2 was not previously recognized as a therapeutic target as it is secreted. It has now been demonstrated that KLK2 is expressed on the cell surface and targetable by various methodologies.

查看原文本刊更多论文

前列腺癌的药物靶点：对klk2介导的破坏的胃口。

人Kallikrein 2 （KLK2）是一种受雄激素受体（AR）信号调节的前列腺癌组织特异性蛋白。由于KLK2是分泌的，因此以前未被认为是一种治疗靶点。现在已经证明，KLK2在细胞表面表达，并可通过各种方法靶向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.